
CANF Stock Forecast & Price Target
CANF Analyst Ratings
Bulls say
Can Fite Biopharma is a clinical-stage biopharmaceutical company with a pipeline of potentially promising drugs targeting the A3 adenosine receptor. Key drivers of this positive outlook include a strong clinical pipeline, encouraging Phase 2a findings, planned Phase 2b combination study in pancreatic cancer, and projected future revenues through 2032. However, potential risks to the thesis include commercial, regulatory, and clinical concerns. Based on a risk analysis and projected financials, we estimate a 12-month price target of $5.00 per ADS for Can Fite Biopharma.
Bears say
Can Fite Biopharma is a clinical-stage biopharmaceutical company with a negative outlook due to several factors. Despite showing favorable safety profiles and clinical activity in Phase 2a trials for pancreatic cancer, the company's drug candidate Piclidenoson has not demonstrated significant efficacy or attracted industry attention, indicating potential issues with its effectiveness. Additionally, while a planned Phase 2b study may improve visibility, the company's focus on a combination immunotherapy strategy in this field is an unproven approach, and the limited treatment options available for pancreatic cancer could make it difficult for the company to stand out in this competitive market.
This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.
CANF Analyst Forecast & Price Prediction
Start investing in CANF
Order type
Buy in
Order amount
Est. shares
0 shares